The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 37, Issue 4, 2013, Pages 823-834

  Cheng, Xiaorui ^a   Zhou, Yu ^a   Gu, Wei ^a   Wu, Jie ^a   Nie, Aihua ^a   Cheng, Junping ^a   Zhou, Jinwu ^a   Zhou, Wenxia ^a   Zhang, Yongxiang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Alzheimer's disease; amyloid ; inhibitor; site A PP cleaving enzyme 1

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BETA SECRETASE 1; BETA SECRETASE 2; BETA SECRETASE INHIBITOR; CATHEPSIN D; COMPOUND VIA; RENIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; IC 50; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; AMYLOID-Β; INHIBITOR; Β-SITE AΒPP CLEAVING ENZYME 1;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; PC12 CELLS; PROTEASE INHIBITORS; RATS;

EID: 84892721613     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130836     Document Type: Article

References (70)

1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
2. Citron M (2010) Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
3. Hook V, Schechter I, Demuth HU, Hook G (2008) Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol Chem 389, 993-1006.
4. Cole SL, Vassar R (2007) The Alzheimer's disease betasecretase enzyme, BACE1. Mol Neurodegener 2, 22.
5. Fleck D, Garratt AN, Haass C, Willem M (2011) BACE1 dependent neuregulin proteolysis: Review. Curr Alzheimer Res 9, 178-183.
6. Citron M (2004) Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5, 677-685.
7. Ghosh AK, Brindisi M, Tang J (2012) Developing betasecretase inhibitors for treatment of Alzheimer's disease. J Neurochem 120(Suppl 1), 71-83.
8. Schechter I, Ziv E (2008) Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional betasecretase candidate(s). Biol Chem 389, 313-320.
9. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottolenghi S, Taramelli R (2000) The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett 468, 59-64.
10. Andrau D, Dumanchin-Njock C,Ayral E,Vizzavona J, Farzan M, Boisbrun M, Fulcrand P, Hernandez JF, Martinez J, Lefranc-Jullien S, Checler F (2003) BACE1- and BACE2- expressing human cells: Characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors. J Biol Chem 278, 25859-25866.
11. Gruninger-Leitch F, Schlatter D, Kung E, Nelbock P, Dobeli H (2002) Substrate and inhibitor profile of BACE (betasecretase) and comparison with other mammalian aspartic proteases. J Biol Chem 277, 4687-4693.
12. Schweda F, Friis U,Wagner C, Skott O,KurtzA(2007) Renin release. Physiology (Bethesda) 22, 310-319.
13. Hobart PM, Fogliano M, O'Connor BA, Schaefer IM, Chirgwin JM (1984) Human renin gene: Structure and sequence analysis. Proc Natl Acad Sci U S A 81, 5026-5030.
14. Isacson O, Seo H, Lin L, Albeck D, Granholm AC (2002) Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci 25, 79-84.
15. Postina R (2008) A closer look at alpha-secretase. Curr Alzheimer Res 5, 179-186.
16. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10, 243-254.
17. Reiserer RS, Harrison FE, Syverud DC, McDonaldMP(2007) Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 6, 54-65.
18. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18, 602-617.
19. Lalonde R, Kim HD, Maxwell JA, Fukuchi K (2005) Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett 390, 87-92.
20. Lalonde R, Kim HD, Fukuchi K (2004) Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Neurosci Lett 369, 156-161.
21. Ghosh AK, Shin D, Koelsch G, Lin X, Ermolieff J, Tang J (2000) Design of potent inhibitors for human brain memapsin 2 (-secretase). J Am Chem Soc 122, 3522-3523.
22. Ghosh AK, Brindisi M, Tang J (2012) Developing betasecretase inhibitors for treatment of Alzheimer's disease. J Neurochem 120(Suppl 1), 71-83.
23. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases -cleavage of amyloid precursor protein and amyloid- production in vivo. J Neurochem 100, 802-809.
24. Takahashi H, Fukumoto H, Maeda R, Terauchi J, Kato K, Miyamoto M (2010) Ameliorative effects of a noncompetitive BACE1 inhibitor TAK-070 on A- peptide levels and impaired learning behavior in aged rats. Brain Res 1361, 146-156.
25. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates A- pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 30, 11157-11166.
26. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB, Reddy DS, Weerasena V, Turner R, Chang W, Koelsch G, Tang J (2008) Potent memapsin 2 (betasecretase) inhibitors: Design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 18, 1031-1036.
27. Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, Davis DL, Gailunas AF, Thorsett ED, Sinha S, Knops JE, Jewett NE, Anderson JP, John V (2003) Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. J Med Chem 46, 1799-1802.
28. Kimura T, Shuto D, Hamada Y, Igawa N, Kasai S, Liu P, Hidaka K, Hamada T, Hayashi Y, Kiso Y (2005) Design and synthesis of highly active Alzheimer's -secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 15, 211-215.
29. Kimura T, Hamada Y, Stochaj M, Ikari H, Nagamine A, Abdel-Rahman H, Igawa N, Hidaka K, Nguyen JT, Saito K, Hayashi Y, Kiso Y (2006) Design and synthesis of potent -secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. Bioorg Med Chem Lett 16, 2380-2386.
30. Hamada Y, Igawa N, Ikari H, Ziora Z, Nguyen JT, Yamani A, Hidaka K, Kimura T, Saito K, Hayashi Y, Ebina M, Ishiura S, Kiso Y (2006) -Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg Med Chem Lett 16, 4354-4359.
31. Wangsell F, Nordeman P, Savmarker J, Emanuelsson R, Jansson K, Lindberg J, Rosenquist S, Samuelsson B, Larhed M (2011) Investigation of alpha-phenylnorstatine and alphabenzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors. Bioorg Med Chem 19, 145-155.
32. Wangsell F, Russo F, Savmarker J, Rosenquist A, Samuelsson B, Larhed M (2009) Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic. Bioorg Med Chem Lett 19, 4711-4714.
33. Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS, Walker DE, Davis D, Thorsett ED, Jewett NE, Moon JB, John V (2004) Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 47, 158-164.
34. Wangsell F, Gustafsson K, Kvarnstrom I, Borkakoti N, Edlund M, Jansson K, Lindberg J, Hallberg A, Rosenquist A, Samuelsson B (2010) Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core. Eur J Med Chem 45, 870-882.
35. Meredith JA, Bjorklund C, Adolfsson H, Jansson K, Hallberg A, Rosenquist A, Samuelsson B (2010) P2-truncated BACE- 1 inhibitors with a novel hydroxethylene-like core. Eur J Med Chem 45, 542-554.
36. Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jin G, Lin L, Lovering FE, Malamas MS, Stahl ML, Strand J, Sukhdeo MN, Svenson K, Turner MJ, Wagner E, Wu J, Zhou P, Bard J (2006) Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 49, 6158-6161.
37. Malamas MS, Erdei J, Gunawan I, Barnes K, Johnson M, Hui Y, Turner J, Hu Y, Wagner E, Fan K, Olland A, Bard J, Robichaud AJ (2009) Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem 52, 6314-6323.
38. Malamas MS, Erdei J, Gunawan I, Turner J, Hu Y, Wagner E, Fan K, Chopra R, Olland A, Bard J, Jacobsen S, Magolda RL, Pangalos M, Robichaud AJ (2010) Design and synthesis of 5,5-disubstituted aminohydantoins as potent and selective human -secretase (BACE1) inhibitors. J Med Chem 53, 1146-1158.
39. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, Winter HL, Reynolds CH, Tounge BA, Luo C, Scott MK, Huang Y, Braeken M, Pieters SM, Berthelot DJ, Masure S, Bruinzeel WD, Jordan AD, Parker MH, Boyd RE, Qu J, Alexander RS, Brenneman DE, Reitz AB (2007) 2-Amino- 3,4-dihydroquinazolines as inhibitors of BACE-1 (-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 50, 4261-4264.
40. Ghosh AK (2010) Introduction to the aspartic proteinase family. In Aspartic Acid Proteases as Therapeutic Targets, Mannhold R, Kubinyi H, Folkers G, eds., Weinheim, pp. 441-479.
41. Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C (2007) A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl 46, 3689-3692.
42. Zhu Y, Xiao K, Ma L, Xiong B, Fu Y, Yu H, Wang W, Wang X, Hu D, Peng H, Li J, Gong Q, Chai Q, Tang X, Zhang H, Li J, Shen J (2009) Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg Med Chem 17, 1600-1613.
43. Huang W, Lv D, Yu H, Sheng R, Kim SC, Wu P, Luo K, Li J, Hu Y (2010) Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease. Bioorg Med Chem 18, 5610-5615.
44. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 100, 802-809.
45. ChangWP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J (2011) Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline inAPPtransgenic mice. FASEB J 25, 775-784.
46. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 30, 11157-11166.
47. Maillard MC, Hom RK, Benson TE, Moon JB, Mamo S, Bienkowski M, Tomasselli AG, Woods DD, Prince DB, Paddock DJ, Emmons TL, Tucker JA, Dappen MS, Brogley L, Thorsett ED, Jewett N, Sinha S, John V (2007) Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 50, 776-781.
48. KortumSW, Benson TE, Bienkowski MJ,EmmonsTL, Prince DB, Paddock DJ, Tomasselli AG, Moon JB, LaBorde A, TenBrink RE (2007) Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1. Bioorg Med Chem Lett 17, 3378-3383.
49. Freskos JN, Fobian YM, Benson TE, Bienkowski MJ, Brown DL, Emmons TL, Heintz R, Laborde A, McDonald JJ, MischkeBV, Molyneaux JM, Moon JB, Mullins PB, Bryan Prince D, Paddock DJ, Tomasselli AG,Winterrowd G (2007) Design of potent inhibitors of human beta-secretase. Part 1. Bioorg Med Chem Lett 17, 73-77.
50. Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, East P, Hawkins J, Howes C, Hussain I, Jeffrey P, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D,Walter DS,Wayne G (2008) Second generation of hydroxyethylamine BACE-1 inhibitors: Optimizing potency and oral bioavailability. J Med Chem 51, 3313-3317.
51. Iserloh U,WuY, Cumming JN, Pan J,WangLY, StamfordAW, Kennedy ME, Kuvelkar R, Chen X, Parker EM, Strickland C, Voigt J (2008) Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg Med Chem Lett 18, 414-417.
52. Cumming JN, Le TX, Babu S, Carroll C, Chen X, Favreau L, Gaspari P, Guo T, Hobbs DW, Huang Y, Iserloh U, Kennedy ME, Kuvelkar R, Li G, Lowrie J, McHugh NA, Ozgur L, Pan J, Parker EM, Saionz K, Stamford AW, Strickland C, Tadesse D, Voigt J, Wang L, Wu Y, Zhang L, Zhang Q (2008) Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. Bioorg Med Chem Lett 18, 3236-3241.
53. Cumming J, Babu S, Huang Y, Carrol C, Chen X, Favreau L, Greenlee W, Guo T, Kennedy M, Kuvelkar R, Le T, Li G, McHugh N, Orth P, Ozgur L, Parker E, Saionz K, Stamford A, Strickland C, Tadesse D,Voigt J, Zhang L, ZhangQ(2010) Piperazine sulfonamide BACE1 inhibitors: Design, synthesis, and in vivo characterization. BioorgMed Chem Lett 20, 2837- 2842.
54. Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DW, Brogley L, John V, Tung JS, Pleiss MA, Tucker JA, Konradi AW, Dappen MS, Toth G, Pan H, Ruslim L, Miller J, Bova MP, Sinha S, Quinn KP, Sauer JM (2009) Design and synthesis of cell potent BACE-1 inhibitors: Structure-activity relationship of P1- substituents. Bioorg Med Chem Lett 19, 6386-6391.
55. Truong AP, Probst GD, Aquino J, Fang L, Brogley L, Sealy JM,HomRK,Tucker JA, JohnV,Tung JS, PleissMA,Konradi AW, Sham HL, Dappen MS, Toth G, Yao N, Brecht E, Pan H, Artis DR, Ruslim L, Bova MP, Sinha S, Yednock TA, Zmolek W, Quinn KP, Sauer JM (2010) Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structure-activity relationship of P2- substituents. Bioorg Med Chem Lett 20, 4789-4794.
56. Rajapakse HA, Nantermet PG, Selnick HG, Munshi S, McGaughey GB, Lindsley SR, Young MB, Lai MT, Espeseth AS, Shi XP, Colussi D, Pietrak B, Crouthamel MC, Tugusheva K, Huang Q, Xu M, Simon AJ, Kuo L, Hazuda DJ, Graham S, Vacca JP (2006) Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 49, 7270-7273.
57. Stauffer SR, Stanton MG, Gregro AR, Steinbeiser MA, Shaffer JR, Nantermet PG, Barrow JC, Rittle KE, Collusi D, Espeseth AS, Lai MT, Pietrak BL, Holloway MK, McGaughey GB, Munshi SK, Hochman JH, Simon AJ, Selnick HG, Graham SL, Vacca JP (2007) Discovery and SAR of isonicotinamideBACE-1 inhibitors that bind beta-secretase in a N-terminal 10s-loop down conformation. Bioorg Med Chem Lett 17, 1788-1792.
58. Stanton MG, Stauffer SR, Gregro AR, Steinbeiser M, Nantermet P, Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Ellis J, Lai MT, Espeseth AS, Shi XP, Jin L, Colussi D, Pietrak B, Huang Q, Xu M, Simon AJ, Graham SL, Vacca JP, Selnick H (2007) Discovery of isonicotinamide derived beta-secretase inhibitors: In vivo reduction of beta-amyloid. J Med Chem 50, 3431-3433.
59. Nantermet PG, Rajapakse HA, Stanton MG, Stauffer SR, Barrow JC, Gregro AR, Moore KP, Steinbeiser MA, Swestock J, Selnick HG, Graham SL, McGaughey GB, Colussi D, LaiMT, Sankaranarayanan S, Simon AJ, Munshi S, Cook JJ, Holahan MA, Michener MS, Vacca JP (2009) Evolution of tertiary carbinamine BACE-1 inhibitors: Abeta reduction in rhesus CSF upon oral dosing. ChemMedChem 4, 37-40.
60. Zhu H, Young MB, Nantermet PG, Graham SL, Colussi D, Lai MT, Pietrak B, Price EA, Sankaranarayanan S, Shi XP, Tugusheva K, Holahan MA, Michener MS, Cook JJ, Simon A, Hazuda DJ, Vacca JP, Rajapakse HA (2010) Rapid P1 SAR of brain penetrant tertiary carbinamine derivedBACE inhibitors. Bioorg Med Chem Lett 20, 1779-1782.
61. Lindsley SR, Moore KP, Rajapakse HA, Selnick HG, Young MB, Zhu H, Munshi S, Kuo L, McGaughey GB, Colussi D, Crouthamel MC, Lai MT, Pietrak B, Price EA, Sankaranarayanan S, Simon AJ, Seabrook GR, Hazuda DJ, Pudvah NT, Hochman JH, Graham SL, Vacca JP, Nantermet PG (2007) Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 17, 4057-4061.
62. Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi XP, Chen-Dodson E, HollowayMK, Munshi S, Simon AJ, Kuo L, Vacca JP (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem 47, 6447-6450.
63. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, Jin L, Ellis J, Holloway MK, Munshi S, Allison T, Hazuda D, Simon AJ, Graham SL, Vacca JP (2006) Macrocyclic inhibitors of beta-secretase: Functional activity in an animal model. J Med Chem 49, 6147-6150.
64. Lerchner A, Machauer R, Betschart C, Veenstra S, Rueeger H, McCarthy C, Tintelnot-Blomley M, Jaton AL, Rabe S, Desrayaud S, Enz A, Staufenbiel M, Paganetti P, Rondeau JM, Neumann U (2010) Macrocyclic BACE-1 inhibitors acutely reduce A- in brain after po application. Bioorg Med Chem Lett 20, 603-607.
65. Yi Mok N, Chadwick J, Kellett KA, Hooper NM, Johnson AP, Fishwick CW (2009) Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg Med Chem Lett 19, 6770-6774.
66. Xu W, Chen G, Zhu W, Zuo Z (2010) Identification of a submicromolar, non-peptide inhibitor of beta-secretase with low neural cytotoxicity through in silico screening. Bioorg Med Chem Lett 20, 5763-5766.
67. XuW, Chen G, ZhuW, Zuo Z (2010) Molecular docking and structure-activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors. Bioorg Med Chem Lett 20, 6203-6207.
68. Hanessian S, Shao Z, Betschart C, Rondeau JM, Neumann U, Tintelnot-Blomley M (2010) Structure-based design and synthesis of novel P2/P3 modified, non-peptidic -secretase (BACE-1) inhibitors. Bioorg Med Chem Lett 20, 1924-1927.
69. Sasaki H, Miki K, Kinoshita K, Koyama K, Juliawaty LD, Achmad SA, Hakim EH, Kaneda M, Takahashi K (2010) - Secretase (BACE-1) inhibitory effect of biflavonoids. Bioorg Med Chem Lett 20, 4558-4560.
70. Asso V, Ghilardi E, Bertini S, Digiacomo M, Granchi C, Minutolo F, Rapposelli S, Bortolato A, Moro S, Macchia M (2008) alpha-Naphthylaminopropan-2- ol Derivatives as BACE1 inhibitors. ChemMedChem 3, 1530-1534.